Journal article
TMOD-15. CHARACTERIZATION OF THE MINIMAL RESIDUAL DISEASE STATE REVEALS DISTINCT EVOLUTIONARY TRAJECTORIES OF HUMAN GLIOBLASTOMA
Abstract
Abstract
Recurrence of solid tumors renders patients vulnerable to a distinctly advanced, highly treatment-refractory disease state that has an increased mutational burden and novel oncogenic drivers not detected at initial diagnosis. Improving outcomes for recurrent cancers requires a better understanding of cancer cell populations that expand from the post-therapy, minimal residual disease (MRD) state. We profiled barcoded …
Authors
Qazi M; Salim S; Brown KR; Savage N; Mickolajewicz N; Han H; Chokshi CR; Mansouri A; Venugopal C; Kislinger T
Journal
Neuro-Oncology, Vol. 23, No. Supplement_6, pp. vi218–vi218
Publisher
Oxford University Press (OUP)
Publication Date
November 12, 2021
DOI
10.1093/neuonc/noab196.876
ISSN
1522-8517